<DOC>
	<DOCNO>NCT01544894</DOCNO>
	<brief_summary>The purpose study compare compliance efficacy raloxifene strontium ranelate group woman postmenopausal osteoporosis .</brief_summary>
	<brief_title>Clinical Study Raloxifene Strontium Ranelate Postmenopausal Osteoporosis</brief_title>
	<detailed_description>OBJECTIVE : To compare performance raloxifene strontium rannelate management woman postmenopausal osteoporosis . DESIGN : Prospective , open label study . SETTING : University hospital menopause unit . PATIENTS : 80 woman postmenopausal osteoporosis assign either raloxifene ( 60 mg/d ) strontium ranelate ( 2g/d ) . Participants follow 1 year . MAIN OUTCOME MEASURE ( S ) : Compliance regime . Secondary objective parameter efficacy , include change bone mineral density bone biochemical marker .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Strontium ranelate</mesh_term>
	<criteria>Postmenopausal woman densitometric osteoporosis Secondary osteoporosis</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Postmenopausal osteoporosis</keyword>
	<keyword>Compliance</keyword>
	<keyword>Bone mineral density</keyword>
	<keyword>Bonemarkers</keyword>
</DOC>